ClinicalTrials.gg
RecruitingNCT06297863DOWN-SUITEUpdated May 6, 2026

Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke

A Phase 2 interventional study of HEAD DOWN TILT -10° to -15° in Acute Ischemic Stroke, sponsored by University of Milano Bicocca. Recruiting at 6 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Milano Bicocca · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.

Planned enrollment
31st of 50
118 · median 227
Started
2025
with 10 others
Phase 2
4 of 81
1 open now
Primary completion
2026-09
later than 8 of 28 live
Registered
65th of 81
by date

Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 31st largest by planned enrollment of the 50 interventional ones that give a count, is one of 11 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 8 of the 28 other live ones, and was the 65th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Ischemic Stroke with a site in Italy, or all of them as a file.
02

Study summary

The DOWN-SUITE study is multicenter, randomised, controlled, open-label clinical trial with blinded outcome assessment comparing collateral status in patients with acute ischemic stroke treated with an in-hospital application of head down tilt -10° to -15° (HDT15) versus usual positioning (0° to +30°) before endovascular mechanical thrombectomy.

This study will involve adult patients who are eligible for mechanical thrombectomy and who have acute ischemic stroke due to left or right middle cerebral artery occlusion (M1 segment).

The investigators hypothesise that HDT15, applied in acute ischemic stroke patients with a large vessel occlusion, will improve collateral circulation, prolong the survival of the ischemic penumbra and improve the clinical benefit from mechanical thrombectomy compared with standard of care (usual positioning 0° to +30°).

Read the detailed description

Investigating, developing and implementing a collateral therapeutic is a major objective in stroke research. The aim is to increase the amount of potentially salvageable penumbral tissue and expand the tissue time window, thus increasing the efficacy of reperfusion therapies and improving clinical outcomes.

Head down tilt 15° (HDT15) is a positional therapy consisting of tilting the patient with the head 15 degrees below the rest of the body. Experimental studies from an Italian-French group (Dr. Simone Beretta, Fondazione IRCCS San Gerardo dei Tintori and Prof. Tae-Hee Cho, Hospices Civils de Lyon) showed that HDT15 increased cerebral blood flow and improved functional outcome and infarct volume in randomised rats with middle cerebral artery (MCA) occlusion followed by reperfusion. Subsequent perfusion MRI experiments using the same stroke model by our group confirmed that HDT15 application for 60 minutes significantly increases collateral flow in the ischemic area.

There is no consensus in current clinical practice regarding the most appropriate head position for acute ischemic stroke (AIS) patients. The sitting position at +30° is the most common. An international cluster-randomised trial, HeadPoST, randomised over 11000 patients with acute stroke (85% ischemic) to either a lying-flat position or a sitting-up position (head elevated to at least 30°), maintained for 24 hours. No difference in the primary efficacy outcome (disability at 90 days measured with the modified Rankin Scale (mRS)), mortality, or rates of other serious adverse events, including pneumonia, were observed. However, the HeadPoST trial primarily targeted patients with mild symptoms without a large vessel occlusion (LVO), who were randomised beyond the usual time window of reperfusion therapies.

One retrospective study (pre-thrombectomy era) compared two cohorts of AIS patients with a LVO: patients with a standard position (0 to 30°; N=119), versus those with a HDT15 position (0 to -15°; N=90). The results suggested that HDT15 promotes neurological improvement compared to the standard position. No difference in serious adverse events was observed between the two cohorts.

A recent randomized, pilot clinical trial showed promising results of -20° head down positioning on long-term disability and an excellent safety profile.

Thus, the available clinical evidence raised no safety concern for HDT15 in AIS patients, but data on its efficacy, notably among AIS patients treated by MT, remains insufficient. HDT15, for its simplicity, low cost and feasibility, might be an optimal collateral therapeutic candidate to prolong the survival of the ischemic penumbra and improve the clinical benefit from reperfusion therapies with disability reduction. HDT15 is readily feasible by Emergency Services in the prehospital phase of AIS, before reperfusion therapies.

The DOWN-SUITE study will be the first multicenter, randomised, controlled, open-label clinical trial with blinded outcome assessment comparing collateral status in patients with AIS treated with an in-hospital application of HDT15 versus usual positioning before MT. The duration of HDT15 application (approximately 60-90 minutes) is expected to be long enough to detect significant changes in cerebral hemodynamics. Building from preclinical experiments on rodent and non-human primate stroke models carried out by our French-Italian group, it will provide for the first time the translation of HDT15 efficacy on cerebral hemodynamics and clinical outcome from animal models to AIS patients.

No therapeutic intervention is currently available to enhance collaterals in AIS.

The DOWN-SUITE trial will provide robust, high-quality evidence on the safety, feasibility and efficacy of HDT15 as a low-cost collateral therapeutic for AIS.

The investigators hypothesise that HDT15 (-10° to -15°), applied in AIS patients with an LVO, will improve collateral circulation, prolong the survival of the ischemic penumbra and improve the clinical benefit from MT compared with standard of care (usual positioning: 0° to +30°).

The investigators aim to perform a prospective, multicenter, proof of concept, randomised, controlled, open-label study. As a double-blind is not possible, a blinded central imaging core lab, whose members will be unaware of the procedure assignments, will assess all imaging outcomes, including the primary efficacy outcome.

This study will involve adult patients who are eligible for MT and who have AIS due to left or right MCA occlusion (M1 segment).

Benefit/risk ratio The investigators hypothesise that HDT15 would improve cerebral collaterals in patients randomised in the intervention group, which could subsequently reduce the ischemic injury and improve the clinical outcome.

No harm from participating in DOWN-SUITE is expected for patients in the intervention or control groups. Previous clinical data on HDT15 raised no safety concerns. No difference in post-stroke complications, including cerebral oedema or haemorrhage, pneumonia or mortality, was observed in a retrospective observational study. HDT15 is not expected to interfere with standard care, including the procedural steps of MT. Mild discomfort related to the tilted position may occur in some patients. The treating physician will continuously monitor all patients during the entire duration of the HDT15 application. No additional risk is expected in patients in the control group, as they will receive standard care.

Overall, this study's benefit/risk ratio is considered very favourable.

This study could potentially establish HDT15 as the first evidence-based collateral therapeutic for AIS. No therapeutic intervention is currently available to enhance collaterals in the acute phase of ischemic stroke. Such a collateral-enhancing therapy is necessary to expand the time window and increase the probability of successful reperfusion with IVT and MT, resulting in better clinical outcomes.

The results of the DOWN-SUITE trial may pave the way for larger randomised controlled trials of HDT15 in a wider stroke patient population, such as patients transferred from spoke hospitals to hub stroke centers to receive thrombectomy and unselected patients with suspected AIS in the prehospital setting.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Collaterals
  • Cerebral hemodynamics
  • Head down positioning
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute ischemic stroke due to left or right MCA occlusion of the M1 segment (excluding occlusion of the internal carotid artery terminus + M1)
  • Decision to treat with mechanical thrombectomy (with or without intravenous thrombolysis)
  • obtained from patient or patient's next of kin, or emergency consent procedure

Exclusion criteria

Exclusion Criteria:

  • Impaired consciousness, defined as NIHSS score of 2 or 3 of the item 1a (level of consciousness): not alert, requires repeated stimulation or unresponsive.
  • Vomiting upon stroke onset.
  • History of glaucoma.
  • History or imaging findings of intracranial hypertension of any aetiology
  • Major breath disorders, defined as follows:

    • oxygen saturation ≤92% in room air at admission
    • severe (COPD) treated with long-term oxygen therapy.
    • severe heart failure with class 3 or 4 (breathlessness during ordinary physical activity or at rest).
  • Severe obesity, defined as (BMI) > 35.
  • Patients participating in another interventional trial that would interfere with this study.
  • Female patients who are pregnant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    HEAD DOWN TILT -10° to -15° (HDT15)

    HDT15 will be applied in the intervention group in 2 different settings: * in the Emergency Room, by tilting the stretcher to lower the head by -10° to -15° relative to the body of the patient; the degree of tilting will be checked using a dedicated digital inclinometer or a mobile phone app * in the Angiography Suite, by tilting the angiography table to lower the head by -10° to -15° relative to the body of the patient, depending on the actual technology of the angiography system of each clinical site; the degree of tilting will be automatically checked using the angiography system HDT15 will start as soon as possible following randomisation in the Emergency Room (i.e. after vascular neuroimaging), and will be maintained during the transfer to the Angiography Suite, as well as during the entire thrombectomy procedure. HDT15 will end after the completion of mechanical thrombectomy.

    Procedure: HEAD DOWN TILT -10° to -15°

  • No intervention
    USUAL POSITIONING

    Patients randomised in the control group will be maintained in the usual position during the emergency room phase (0° to +30°) and on the angiography table (0°), according to standard practice. Mechanical thrombectomy will be performed as per usual care.

Interventions

  • ProcedureHEAD DOWN TILT -10° to -15°

    Head down tilt -10° to -15° (HDT15) is a positional therapy consisting of tilting the patient with the head -10° to -15° degrees below the rest of the body. Application of HDT15 will not delay usual care. The standard in-hospital patient pathway, including transfer from neuroimaging room to the angiography suite and the required procedural steps of MT, will allow sufficient time for the application of HDT15. HDT15 duration is expected to be at least 30 minutes (estimated time 30 to 90 minutes), from start to the assessment of the primary efficacy endpoint. The actual degree of HDT15 will be a range between -10° to -15°, depending on the angiographic system of each clinical site, but it will be maintained at -15° during the Emergency Room phase which is expected to account for \>50% of the total application time.

06

What researchers measure

Primary outcomes

  1. Good collateral status

    The primary endpoint will be the achievement of good collateral status, i.e. grade 3 or 4 on the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) collateral scale, in the HDT15 versus control group, as seen at the beginning of MT.15 The ASITN/SIR collateral grade will be assessed by a blinded central imaging core lab from the pretreatment diagnostic angiographic runs, routinely performed as the first procedural step of MT.

    Time frame: Day 0 (during mechanical thrombectomy)

Secondary outcomes

  1. Feasibility of HDT15

    proportion of patients randomised to the intervention group who are able to maintain HDT15 during the entire MT procedure

    Time frame: Day 0 (in the emergency room and angio suite)

  2. Delay to thrombectomy

    hospital admission-to-arterial access time (i.e. time to arterial puncture)

    Time frame: Day 0 (in the emergency room and angio suite)

  3. Vomiting

    Proportion of patients presenting one or more episodes of vomiting from randomisation to the completion of MT

    Time frame: Day 0 (in the emergency room and angio suite)

  4. Early neurological deterioration

    Proportion of patients who had increase of ≥4 points on the NIHSS score within 24±12 hours of the randomisation

    Time frame: 1 day (24±12 hours)

  5. Symptomatic intracranial hemorrhage

    Proportion of patients who had SICH per SITS-MOST definition within 24±12 hours: type 2 parenchymal hematoma with neurological deterioration of ≥4 points on the NIHSS

    Time frame: 1 day (24±12 hours)

  6. Aspiration pneumonia

    Proportion of patients with pneumonia within the first 72 hours after randomisation

    Time frame: 1 day (24±12 hours)

  7. Neurological disability

    functional outcome at 3 months, assessed with the ordinal score on the modified Rankin scale (shift across outcomes on the mRS between groups)

    Time frame: 3 months

  8. Systolic blood pressure

    Mean values of systolic blood pressure (mmHg) from hospital admission to the end of MT; monitored at entry in the Emergency Room, at entry in the angio suite and every 15 minutes from the start to the end of MT

    Time frame: Day 0 (in the emergency room and angio suite)

  9. Diastolic blood pressure

    Mean values of diastolic blood pressure (mmHg) from hospital admission to the end of MT; monitored at entry in the Emergency Room, at entry in the angio suite and every 15 minutes from the start to the end of MT

    Time frame: Day 0 (in the emergency room and angio suite)

  10. Oxygen saturation

    Mean values of oxygen saturation (%) from hospital admission to the end of MT; these physiological parameters will be monitored at entry in the Emergency Room, at entry in the angio suite and every 15 minutes from the start to the end of MT

    Time frame: Day 0 (in the emergency room and angio suite)

07

Study locations

1 of 6 sites recruiting
  • Ospedale Civile SS. Nicola e Filippo Avezzano Pronto Soccorso
    Avezzano, 67051, Italy
    Not yet recruiting
    • Simona Sacco, MD, PhD · Principal investigator
  • Azienda Ospedaliero Universitaria Careggi
    Florence, 50134, Italy
    Not yet recruiting
    • Enrico Fainardi, MD, PhD · Principal investigator
  • Azienda Ospedaliera Policlinico Universitario "G. Martino"
    Messina, 98124, Italy
    Not yet recruiting
    • Sergio Vinci, MD, PhD · Principal investigator
  • Fondazione IRCCS San Gerardo dei Tintori Monza
    Monza, 20900, Italy
    Recruiting
    • Simone Beretta, MD, PhD · Principal investigator
  • Azienda Ospedaliero Universitaria Policlinico Umberto I
    Roma, 00161, Italy
    Not yet recruiting
    • Danilo Toni, MD, PhD · Principal investigator
  • Ospedale Santa Maria della Misericordia
    Udine, 33100, Italy
    Not yet recruiting
    • Francesco Janes, MD, PhD · Principal investigator
08

References and documents

Publications

  • Beretta S, Versace A, Carone D, Riva M, Dell'Era V, Cuccione E, Cai R, Monza L, Pirovano S, Padovano G, Stiro F, Presotto L, Paterno G, Rossi E, Giussani C, Sganzerla EP, Ferrarese C. Cerebral collateral therapeutics in acute ischemic stroke: A randomized preclinical trial of four modulation strategies. J Cereb Blood Flow Metab. 2017 Oct;37(10):3344-3354. doi: 10.1177/0271678X16688705. Epub 2017 Jan 23. PubMed 28112023 ↗
  • Diamanti S, Mariani J, Versace A, Riva M, Cuccione E, Cai R, Monza L, Vigano M, Bolbos R, Chauveau F, Cho TH, Carone D, Ferrarese C, Beretta S. Head down tilt 15 degrees to preserve salvageable brain tissue in acute ischemic stroke: A pre-clinical pooled analysis, with focus on cerebral hemodynamics. Eur J Neurosci. 2023 Jun;57(12):2149-2159. doi: 10.1111/ejn.15852. Epub 2022 Nov 4. PubMed 36300727 ↗
  • Anderson CS, Arima H, Lavados P, Billot L, Hackett ML, Olavarria VV, Munoz Venturelli P, Brunser A, Peng B, Cui L, Song L, Rogers K, Middleton S, Lim JY, Forshaw D, Lightbody CE, Woodward M, Pontes-Neto O, De Silva HA, Lin RT, Lee TH, Pandian JD, Mead GE, Robinson T, Watkins C; HeadPoST Investigators and Coordinators. Cluster-Randomized, Crossover Trial of Head Positioning in Acute Stroke. N Engl J Med. 2017 Jun 22;376(25):2437-2447. doi: 10.1056/NEJMoa1615715. PubMed 28636854 ↗
  • Gauthier A, Gerardin P, Renou P, Sagnier S, Debruxelles S, Poli M, Rouanet F, Olindo S, Sibon I. Trendelenburg Positioning in Large Vessel Ischaemic Stroke: A Pre-Post Observational Study Using Propensity Score Matching. Cerebrovasc Dis. 2018;46(1-2):24-32. doi: 10.1159/000490423. Epub 2018 Jul 27. PubMed 30056454 ↗
  • Chen HS, Zhang NN, Cui Y, Li XQ, Zhou CS, Ma YT, Zhang H, Jiang CH, Li RH, Wan LS, Jiao Z, Xiao HB, Li Z, Yan TG, Wang DL, Nguyen TN. A randomized trial of Trendelenburg position for acute moderate ischemic stroke. Nat Commun. 2023 May 5;14(1):2592. doi: 10.1038/s41467-023-38313-y. PubMed 37147320 ↗
  • Pedrazzini FA, Piergallini L, Diamanti S, Fainardi E, Vinci SL, Sozzi C, Fare M, Rossi E, Graziano F, Poggetti F, Mainini G, Giglio A, Magi A, Pederzoli G, Anzani A, De Bernardi E, Cerina V, Cho TH, Chauveau F, Carone D, Basso G, Citerio G, Sarti C, Limbucci N, Janes F, Casella C, Toscano A, Sacco S, Toni D, Remida P, Ferrarese C, Beretta S. Head Down Tilt 15 degrees to Increase Collateral Flow in Acute Ischemic Stroke: Rationale and Study Protocol of a Multicenter, Randomized, Proof-of-Concept, Phase 2a/b Trial in Patients Treated With Mechanical Thrombectomy (DOWN-SUITE). Stroke Vasc Interv Neurol. 2026 Feb 4;6(2):e002221. doi: 10.1161/SVIN.125.002221. eCollection 2026 Mar. PubMed 41815317 ↗

Individual participant data

Plan to share: Yes — The project data can be accessed by interested European and extra-EU third parties for replication or further analysis only if given in a completely anonymous form. Third parties in this project include academic institutions, research centers and non-profit associations (e.g. research consortia). Third parties in this project do not include profit associations (e.g. drug companies).

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: After completion of the primary analysis

Access criteria: If the need arises to communicate data in pseudo-anonymous form, the patient will, first of all, be informed and specific informed consent will be provided. In the latter case, the data will not be sent without the patient's consent. Ad hoc Data Transfer Agreements will be established with the interested third parties.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Sep 2026, 18 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 18 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 7, 2024
StartActual
Mar 1, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06297863
Collaborators
Fondazione IRCCS San Gerardo dei Tintori, Azienda Ospedaliero-Universitaria Careggi, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, Università degli Studi dell'Aquila, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Mar 1, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Simone Beretta, MD, PhD
Contact
simone.beretta@unimib.it
+390392333568
BiCRO (academic CRO)
Contact
bicro@unimib.it
Simone Beretta, MD, PhD
principal investigator · University of Milano Bicocca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion